The clinical value of serum hepatocyte growth factor levels in patients undergoing primary radiotherapy for glioma: effect on progression-free survival

Medical Oncology

Volumn 31, Issue 9, 2014, Pages 1-6

  Liang, Qing le ^a   Mo, Zheng ying ^a   Wang, Ping ^a   Li, Xiao ^a   Liu, Zhi xiang ^a   Zhou, Zhang ming ^b,c  

^a HUBEI UNIVERSITY OF MEDICINE   (China)

^b SICHUAN UNIVERSITY   (China)

^c Dujiangyan Medical Center   (China)

Author keywords

Angiogenesis; Glioma; Hepatocyte growth factor

Indexed keywords

EID: 84904534507     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0122-5     Document Type: Article

References (38)

1. Abounader R, Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol. 2005;7:436–51.
2. Bian XW, Yang SX, Chen JH, et al. Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival. Neurosurgery. 2007;61:570–8.
3. Brockmann MA, Ulbricht U, Grüner K, et al. Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors. Neurosurgery. 2003;52:1391–9.
4. Eckerich C, Zapf S, Fillbrandt R, et al. Hypoxia can induce c-Met expression in glioma cells and enhance SF/HGF-induced cell migration. Int J Cancer. 2007;12:276–83.
5. Li Y, Lal B, Kwon S, Fan X, et al. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. Cancer Res. 2005;65:9355–62.
6. Uchinokura S, Miyata S, Fukushima T, et al. Role of hepatocyte growth factor activator (HGF activator) in invasive growth of human glioblastoma cells in vivo. Int J Cancer. 2006;118:583–92.
7. Murakami T, Maki W, Cardones AR, et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res. 2002;62:7328–34.
8. Schmidt NO, Westphal M, Hagel C, et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer. 1999;84:10–8.
9. Chu SH, Zhu ZA, Yuan XH, et al. In vitro and in vivo potentiating the cytotoxic effect of radiation on human U251 gliomas by the c-Met antisense oligodeoxynucleotides. J Neurooncol. 2006;80:143–9.
10. Chu SH, Yuan XH, Li ZQ, et al. C-Met antisense oligodeoxynucleotide inhibits growth of glioma cells. Surg Neurol. 2006;65:533–8.
11. Chu SH, Zhang H, Ma YB, et al. C-Met antisense oligodeoxynucleotides as a novel therapeutic agent for glioma: in vitro and in vivo studies of uptake, effects and toxicity. J Surg Res. 2007;141:284–8.
12. Chu SH, Ma YB, Zhang H, et al. Hepatocyte growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells. J Neurooncol. 2007;85:33–8.
13. MacDonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277–80.
14. Camp RL, Rimn EB, Rimm DL. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer. 1999;86:2259–65.
15. Cheng HL, Liu HS, Lin YJ, et al. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br J Cancer. 2005;92:1906–14.
16. Fracchioli S, Katsaros D, Maggiora P, et al. Evaluation of Ron and Met proto-oncogene expression in epithelial ovarian tumors. Minerva Ginecol. 1999;51:359–64.
17. Knudsen BS, Edlund M. Prostate cancer and the met hepatocyte growth factor receptor. Adv Cancer Res. 2004;91:31–67.
18. Linehan WM, Vasselli J, Srinivasan R, et al. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res. 2004;10:6282–9.
19. Narayanan R. Harnessing the power of antisense, technology for combination chemotherapy. J Natl Cancer Inst. 1997;89:107–8.
20. Otte JM, Kiehne K, Schmitz F, et al. C-met protooncogene expression and its regulation by cytokines in the regenerating pancreas and in pancreatic cancer cells. Scand J Gastroenterol. 2000;35:90–5.
21. Shimizu S, Yamada N, Sawada T, et al. In vivo and in vitro interactions between human colon carcinoma cells and hepatic stellate cells. Jpn J Cancer Res. 2000;91:1285–95.
22. Takuzou M, Hiroaki K, Ryoichi H, et al. Up-regulation of vascular endothelial growth factor induced by hepatocyte growth factor/scatter factor stimulation in human glioma cells. Biochem Biophys Res Commun. 1998;249:73–7.
23. Wang SY, Chen B, Zhan YQ, et al. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells. J Hepatol. 2004;41:267–73.
24. Yoshida S, Harada T, Iwabe T, et al. Induction of hepatocyte growth factor in stromal cells by tumor-derived basic fibroblast growth factor enhances growth and invasion of endometrial cancer. J Clin Endocrinol Metab. 2002;87:2376–83.
25. Zou M, Famulski KS, Parhar RS, et al. Microarray analysis of metastasis-associated gene expression profiling in a murine model of thyroid carcinoma pulmonary metastasis: identification of S100A4 (Mts1) gene overexpression as a poor prognostic marker for thyroid carcinoma. Clin Endocrinol Metab. 2004;89:6146–54.
26. Laterra J, Rosen E, Nam M, et al. Scatter factor/hepatocyte growth factor expression enhances human glioblastoma tumorigenicity and growth. Biochem Biophys Res Commun. 1997;235:743–7.
27. Laterra J, Nam M, Rosen E, et al. Scatter factor/hepatocyte growth factor gene transfer to 9L glioma cells enhances glioma growth and angiogenesis in vivo. Lab Invest. 1997;76:565–77.
28. Chu SH, Yuan XH, Jiang PC, et al. Expression of hepatocyte growth factor and its receptor mRNA in brain astrocytomas. Tumor. 2005;25:173–6.
29. Aebersold DM, Kollar A, Beer KT, et al. Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation. Int J Cancer. 2001;96:41–54.
30. Chi CH, Liu IL, Lo WY, et al. Hepatocyte growth factor gene therapy prevents radiation-induced liver damage. World J Gastroenterol. 2005;11:1496–502.
31. Jankowski K, Kucia M, Wysoczynski M, et al. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res. 2003;63:7926–35.
32. Ide T, Kitajima Y, Miyoshi A, et al. Tumor–stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway. Int J Cancer. 2006;119:2750–9.
33. Hara S, Nakashiro K, Klosek SK, et al. Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells. Oral Oncol. 2006;42:593–8.
34. Irie N, Matsuo T, et al. Protocol of radiotherapy for glioblastoma according to the expression of HIF-1. Brain Tumor Pathol. 2004;21:1–6.
35. Evans SM, Judy KD, Dunphy I, et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res. 2004;10:8177–84.
36. Lal B, Xia S, Abounader R, et al. Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. Clin Cancer Res. 2005;11:4479–86.
37. Chu SH, Yuan XH, Jiang PC, et al. Recombinant human hepatocyte growth factor in cellular apoptosis of glioma induced by mitomycin C. Chin J Neuromed. 2005;4:1093–6.
38. Jiang PC, Chu SH, Li ZQ, et al. The c-Met antisense oligodeoxynucleotide enhance the sensitivity of glioma cell U251 to mitomycin C. Chin J Exp Surg. 2006;24:540–2.